Body Systems

Huntington's Disease1 Result found

Closed for recruitment:

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease. A total of approximately 260 subjects are planned to be randomized in the study.

Closed for Recruitment
Principal Investigator 
Lynn A. Raymond
Body Locations and Systems 
Huntington's Disease
Area 
Vancouver
Age 
30-65